Generic Name and Formulations:
Telotristat ethyl 250mg; tabs.
Indications for XERMELO:
In combination with somatostatin analog (SSA) therapy, to treat carcinoid syndrome diarrhea in adults inadequately controlled by SSA therapy.
Take with food. 250mg 3 times daily.
Monitor for constipation and/or severe, persistent, or worsening abdominal pain; discontinue if develops. ESRD requiring dialysis: not studied. Pregnancy. Nursing mothers: monitor infant for constipation.
Tryptophan hydroxylase inhibitor.
May antagonize CYP3A4 substrates (eg, midazolam); monitor and consider increasing dose of concomitant substrates if necessary. Antagonized by short-acting octreotide; if concomitant use is necessary, give dose ≥30mins after Xermelo.
Nausea, headache, increased GGT, depression, flatulence, decreased appetite, peripheral edema, pyrexia.
Monthly carton—4 x 7 daily dose packs
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Characteristics of Unipolar Mania, Distinct from Bipolar Disorder, Described
- Aspirin, N-Acetylcysteine Effective Adjunctive Treatments in Bipolar Depression
- Subthreshold Pediatric Bipolar Disorder Is a Significant Psychiatric Burden
- Potential Biomarker Differentiates Between Bipolar Disorder With, Without Psychosis
- Part 1: Adolescent Tech Use and Mental Health: Expert Roundtable
- Challenging Stigma: Should Psychiatrists Disclose Their Own Mental Illness?
- Social Anxiety in Schizophrenia: An Overlooked Problem
- Inflammation: Is It the Link Between Rheumatoid Arthritis and Depression?
- Childhood Physical Violence Associated With Decreased Total Cholesterol
- How the Government Shutdown Affects FDA Activities
- The Robot Will See You Now: The Increasing Role of Robotics in Psychiatric Care
- Extended-Release Naltrexone Improves Psychiatric Disorders During Addiction Therapy
- Infections, Antibiotics Associated With Subsequent Increased Risk for Mental Disorders in Youth